← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
126	126 Lyell Immunopharma LYEL $201M	–	–	–	–
127	127 Mustang Bio MBIO $2.93M	–	–	–	–
128	128 DELISTED 23andMe Holding Co ME	–	–	–	–
129	129 Mesoblast MESO $1.81B	–	–	–	–
130	130 MeiraGTx Holdings MGTX $950M	–	–	–	–
131	131 Metagenomi Therapeutics MGX $31.9M	–	–	–	–
132	132 Marker Therapeutics MRKR $15.3M	–	–	–	–
133	133 Maravai LifeSciences MRVI $1.05B	–	–	–	–
134	MSGR 134 DELISTED Direxion mRNA ETF MSGR	–	–	–	–
135	135 MaxCyte MXCT $134M	–	–	–	–
136	136 NewcelX Ltd NCEL $16.5M	–	–	–	–
137	137 Neurogene NGNE $479M	–	–	–	–
138	138 DELISTED NKGen Biotech, Inc. Common Stock NKGN	–	–	–	–
139	139 Nkarta NKTX $138M	–	–	–	–
140	140 Intellia Therapeutics NTLA $1.59B	–	–	–	–
141	NVTA 141 DELISTED Invitae Corporation NVTA	–	–	–	–
142	142 OmniAb OABI $688M	–	–	–	–
143	OBX 143 Obsidian Therapeutics OBX $754M	–	–	–	–
144	144 Ocugen OCGN $276M	–	–	–	–
145	145 DELISTED Omega Therapeutics, Inc. Common Stock OMGA	–	–	–	–
146	146 DELISTED Singular Genomics Systems, Inc. Common Stock OMIC	–	–	–	–
147	ONCS 147 DELISTED OncoSec Medical Incorporated ONCS	–	–	–	–
148	148 DELISTED Orgenesis Inc. Common Stock ORGS	–	–	–	–
149	ORTX 149 DELISTED Orchard Therapeutics plc American Depositary Shares ORTX	–	–	–	–
150	150 Passage Bio PASG $11.6M	–	–	–	–